A Weill Cornell Medicine team has found that triple-negative breast cancer depends on the enzyme EZH2 to spread. By silencing key genes, EZH2 drives chaotic cell divisions and fuels metastasis.

Triple negative breast cancer (TNBC) is one of the most aggressive and hardest forms of breast cancer to treat, but a new ...

Mayo Clinic researchers have identified a protein that acts like a traffic controller for DNA, preventing damage during cell ...

Researchers have discovered that an enzyme called EZH2 drives TNBC cells to divide abnormally, which enables them to relocate ...

MIT and Harvard scientists have created engineered CAR-NK cells that can hide from the immune system and more effectively ...

From bispecific engineering to clinically relevant data sourcing, evolving antibody technologies advance oncology therapeutics.

Researchers have refined a powerful DNA sequencing tool that can uncover hidden mutations that occur naturally in our bodies ...

Scientists at City of Hope® have uncovered a gene called SMOC1 that plays a surprising role in the development of type 2 ...

Rising Cancer Incidence Boosts Demand for Circulating Tumor Cell DetectionThe Circulating Tumor Cells (CTCs) market has ...

Cancer researcher Chi Van Dang studies pharmacokinetics—the way the body absorbs, distributes, metabolizes, and excretes a ...

In 2020, right when Jane Baude was starting her Ph.D. research at UC Santa Barbara, she learned that a critical component of her experiment — the ...